Clinical Nutrition

Product description

Glucose Intravenous Infusion Contraindications:

- Elevated blood sugar concentration (hyperglycaemia)
Composition
- Decreased blood potassium concentration (hypokalaemia)
Each 1000 ml solution contains:
- High concentration of acid substances in blood (acidosis)
- Hyperhydration
Glucose - Simultaneous sodium and water deficiency (hypotonic dehydration)
10% 20% 30% 40% 50 % 70 %
Glucose (g) 100 200 300 400 500 700 Special warnings and precautions for use
As glucose monohydrate (g) 110 220 330 440 550 770 This solution should only be administered with caution to patients with increased serum osmolarity.
Carbohydrate contents (g) 100 200 300 400 500 700 Patient monitoring should include regular checks of the blood glucose level, depending on the
Caloric value (kJ/ prevailing metabolic condition and the administered dose. Patient monitoring should also include regular
kcal) 1675/ 3350/ 5025/ 6700/ 8375/ 11725/ checks of the water balance, the serum electrolyte concentrations – in particular serum potassium – and
400 800 1200 1600 2000 2800 the acid-base balance.
Theor. Osmolarity (mOsm/l) 555 1100 1665 2220 2770 3880
Glucose Infusions should not be administered through the same infusion equipment, simultaneously with,
before, or after administration of blood, because of the possibility of pseudo-agglutination.
Indications:
- Energy supply by means of glucose Subject to sale by pharmacists only.
- Carbohydrate component in parenteral nutrition
- Therapy of hypoglycaemia B. Braun Melsungen AG
34209 Melsungen, Germany

sis, severe liver damage, pulmonary disease, sepsis, diseases of the reticuloendothelial system, anaemia or
Lipofundin® N blood coagulation disorders or when there is danger of fat embolism.
Composition Administration of Lipofundin® N should be accompanied by simultaneous carbohydrate infusions making
1000 ml emulsion contains: up to 40% (at least) of the total calorie intake. When Lipofundin® N is administered, the patient’s capaci-
Lipofundin ® N 10% Lipofundin ® N 20% ty to eliminate the infused fat from the circulation must be monitored. The lipaemia must clear between
Soya oil 100.0 g 200.0 g daily infusions. Especially where fat emulsions are administered for extended periods of time, the patient’s
Glycerol 25.0 g 25.0 g haemogram, blood coagulation, liver function and platelet count should be closely monitored.
Egg Lecithin 8.0 g 12 g
Use in pregnancy and lactation:
Sodium Oleate, α- Tocopherol, Water for Injections The safety of Lipofundin® N during pregnancy and lactation has not been assessed, but its use during
Megajoules/l (approx.): 4.5 (1072 kcal) 8.4 (2008 kcal) these periods is not considered to constitute a hazard. Nevertheless, medicines should not be used in
Milliosmols/l (approx.): 345 380 pregnancy, especially during the first trimester, unless the expected benefit is thought to outweigh any
pH: 6.5–8.8 6.5–8.5 possible risk to the foetus.

Indications: Special warnings:

Lipofundin® N is indicated as a source of calories and essential fatty acids for patients requiring
parenteral nutrition.
Contraindications:
The administration of Lipofundin® N is contraindicated in patients demonstrating disturbances in normal
fat metabolism such as pathologic hyperlipaemia, lipoid nephrosis, or acute pancreatitis if
accompanied by hyperlipaemia. It is further contraindicated in patients with ketoacidosis or hypoxia, in
thromboembolism and in acute shock states.
The too rapid infusion of fat emulsions can cause fluid and/or fat overloading resulting in dilution of
serum electrolyte concentrations, overhydration, congested states, pulmonary oedema, impaired pulmo-
nary diffusion capacity. A too rapid infusion of Lipofundin® N can also cause hyperketonaemia and/or
metabolic acidosis, especially when carbohydrates are not administered simultaneously.
Subject to sale by pharmacists only.

Precautions for use: B. Braun Melsungen AG

Caution should be exercised in administering intravenous fat emulsions in patients with metabolic acido- 34209 Melsungen, Germany

Lipofundin® MCT/LCT 1 Indications: 40% (at least) of the total calorie intake. ing these periods is not considered to constitute a
Lipofundin® MCT/LCT is indicated as a source of When Lipofundin® MCT/LCT is administered, the hazard. Nevertheless, medicines should not be used
Composition calories and essential fatty acids for patients requir- patient's capacity to eliminate the infused fat from in pregnancy, especially during the first trimester,
1000 ml emulsion contain ing parenteral nutrition. the circulation must be monitored. The lipaemia unless the expected benefit is thought to outweigh
Lipofundin® Lipofundin® must clear between daily infusions. Especially where any possible risk to the foetus.
MCT/LCT 10% MCT/LCT 20% Contraindications: fat emulsions are administered for extended periods
Soybean oil 50.0 g 100.0 g The administration of Lipofundin® MCT/LCT is con- of time, the patient's haemogram, blood coagula- Special warnings:
Mediumchain Triglycerides 50.0 g 100.0 g traindicated in patients demonstrating disturbances tion, liver function and platelet count should be The too rapid infusion of fat emulsions can cause
Glycerol 25.0 g 25.0 g in normal fat metabolism such as pathologic hyper- closely monitored. fluid and/or fat overloading resulting in dilution of
Egg yolk phospholipids* 8.0 g 12.0 g lipaemia, lipoid nephrosis, or acute pancreatitis if Paediatric patients: studies have shown the safety serum electrolyte concentrations, overhydration,
Sodium Oleate, α-Tocopherol*, Water for injections accompanied by hyperlipaemia. It is further con- and effectiveness of Lipofundin® MCT/LCT as part of congested states, pulmonary oedema, impaired pul-
Megajoules/l (approx.): 4.43 (1022 kcal) 7.99 (1908 kcal) traindicated in patients with ketoacidosis or hypox- total parenteral nutrition in neonates and older monary diffusion capacity. A too rapid infusion of
Milliosmols/l (approx.): 345 380 ia, in thromboembolism and in acute shock states. children. Lipofundin® MCT/LCT can also cause hyperketonae-
pH: 6.5-8.8 6.5-8.5 Lipofundin® MCT/LCT has been aproved for usage in mia and/or metabolic acidosis, especially when car-
Precautions for use: this patient population in some countries. bohydrates are not administered simultaneously.
* The amount of egg yolk phospholipids and
Caution should be exercised in administering intra- Registration procedures are currently pursued in
α-tocopherol can vary is some countries. Please
venous fat emulsions in patients with metabolic other countries. As long as approval has not been Subject to sale by pharmacists only.
refer to the country representative. Soybean oil is a
acidosis, severe liver damage, pulmonary disease, obtained in a specific country it is up to the judge-
refined natural product containing neutral triglycer-
sepsis, diseases of the reticuloendothelial system, ment of the responsible physician whether or not to
ides of predominantly unsaturated fatty acids.
anaemia or blood coagulation disorders or when use Lipofundin® MCT/LCT in this patient group.
Medium-chain triglycerides are a mixture of neutral
there is danger of fat embolism. Administration of Use in pregnancy and lactation
triglycerides of mainly caprylic (about 60%) and
Lipofundin® MCT/LCT should be accompanied by The safety of Lipofundin® MCT/LCT during pregnancy B. Braun Melsungen AG
capric acid (about 40%).
simultaneous carbohydrate infusions making up to and lactation has not been assessed, but its use dur- 34209 Melsungen, Germany

1. Trade name in some countries: Medialipide®, Vasolipid®

Specific Product Information may differ from country to country

29

090423_Clinical_Nutrition.indd 29 23.Apr.09 15:44